Free tool
FAERS Monitor: Relpax
Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021016 or its brand name (Relpax, Eletriptan Hydrobromide). Reports on generic versions are filed under their own applications.
Reports
7,038
Serious
3,693
52% of reports
Hospitalization
1,236
Death reported
97
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective913
- migraine863
- headache733
- nausea502
- pain425
- fatigue335
- vomiting329
- malaise292
- dizziness270
- off label use231
- anxiety223
- feeling abnormal214
- dyspnoea207
- insomnia202
- condition aggravated197
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 208 |
| 2005 | 183 |
| 2006 | 112 |
| 2007 | 131 |
| 2008 | 134 |
| 2009 | 75 |
| 2010 | 322 |
| 2011 | 282 |
| 2012 | 451 |
| 2013 | 408 |
| 2014 | 478 |
| 2015 | 618 |
| 2016 | 689 |
| 2017 | 406 |
| 2018 | 392 |
| 2019 | 672 |
| 2020 | 415 |
| 2021 | 244 |
| 2022 | 256 |
| 2023 | 170 |
| 2024 | 177 |
| 2025 | 129 |
| 2026 | 86 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,121 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| migraineSignal | 863 | 27.3 | 25.6 | 21,701 |
| headacheSignal | 733 | 3.5 | 3.3 | 1,343 |
| feeling abnormalSignal | 214 | 2.7 | 2.3 | 224 |
| anxietySignal | 223 | 2.3 | 2.1 | 172 |
| insomniaSignal | 202 | 2.3 | 2.0 | 144 |
| vomitingSignal | 329 | 2.1 | 1.9 | 191 |
| drug ineffectiveSignal | 913 | 2.1 | 1.9 | 538 |
| painSignal | 425 | 2.1 | 1.9 | 240 |
| malaise | 292 | 2.0 | 1.8 | 146 |
| condition aggravated | 197 | 1.9 | 1.7 | 90 |
| nausea | 502 | 1.9 | 1.7 | 220 |
| dizziness | 270 | 1.6 | 1.4 | 65 |
| fatigue | 335 | 1.3 | 1.2 | 22 |
| dyspnoea | 207 | 1.1 | 1.0 | 2 |
| off label use | 231 | 0.8 | 0.7 | 13 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.